Stone Edwin M
University of Iowa Carver College of Medicine, the Howard Hughes Medical Institute, Iowa City, USA.
Trans Am Ophthalmol Soc. 2003;101:437-84.
To explore two approaches for making the human genome more accessible and useful to practicing ophthalmologists.
DNA samples were obtained from patients with inherited eye diseases, and these samples were screened for sequence variations in known disease genes with a combination of single-strand conformational polymorphism analysis and automated DNA sequencing. Data from this screening were then used to evaluate strategies for productively narrowing the sample space as well as for estimating the pathogenic potential of variations that were discovered in individual patients. For the latter purpose, a universal nomenclature for pathogenic potential was proposed based upon the segregation of disease alleles and the evolutionary conservation of specific residues as reflected by a substitution matrix known as blosum 62.
Sequence variations were found to be unevenly distributed among disease-associated genes, such that screening strategies could be refined to discover more than 50% of clinically important sequence variations with only 10% of the effort. The use of the blosum 62 matrix was more statistically powerful than our previous method of estimating pathogenic probability.
The size of the human genome requires that clinical questions be very carefully focused if they are to be meaningfully answered in a reasonable amount of time and with a reasonable amount of resources. By examining the behavior of known disease genes, one can design strategies for significantly focusing the sample space and for more effectively interpreting the variations that are found.
探索两种使人类基因组对眼科执业医生更易获取且更有用的方法。
从患有遗传性眼病的患者中获取DNA样本,通过单链构象多态性分析和自动化DNA测序相结合的方法,对这些样本进行已知疾病基因的序列变异筛查。然后,利用该筛查数据评估有效缩小样本空间的策略,以及估计个体患者中发现的变异的致病潜力。对于后一个目的,基于疾病等位基因的分离以及由称为blosum 62的替换矩阵所反映的特定残基的进化保守性,提出了一种致病潜力的通用命名法。
发现序列变异在疾病相关基因中分布不均,因此可以优化筛查策略,仅用10%的工作量就能发现超过50%的临床重要序列变异。使用blosum 62矩阵在统计学上比我们之前估计致病概率的方法更具效力。
人类基因组的规模要求,如果要在合理的时间内和合理的资源下有意义地回答临床问题,就必须非常仔细地聚焦临床问题。通过研究已知疾病基因的行为,可以设计出显著聚焦样本空间并更有效地解释所发现变异的策略。